---
title: "Estrella Immunopharma, Inc. (ESLA.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/ESLA.US.md"
symbol: "ESLA.US"
name: "Estrella Immunopharma, Inc."
industry: "Biotechnology"
---

# Estrella Immunopharma, Inc. (ESLA.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [www.estrellabio.com](https://www.estrellabio.com) |

## Company Profile

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company’s lead product candidate is EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is i...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -3.67 | 333/604 | - | - | - |
| PB | -5.04 | 521/604 | 244.07 | 49.43 | 43.63 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-09T05:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.07 |
| Highest Target | 16.00 |
| Lowest Target | 16.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/ESLA.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/ESLA.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/ESLA.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.